Nexsen Enters into Molecular GBS Diagnostic Joint Venture with FlashDx Shenzhen

Nexsen Limited ASX:NXN has entered a non-binding term sheet with FlashDx Shenzhen to establish a 50:50 joint venture focused on developing and commercialising an enhanced molecular Group B Streptococcus (GBS) diagnostic.The proposed JV would build on FlashDx’s existing CE-marked molecular GBS test…